Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Open Access
- 15 March 2014
- journal article
- Published by Springer Nature in BMC Neurology
- Vol. 14 (1) , 51
Abstract
To review our experience using methotrexate as a single long-term immunosuppressant (IS) therapy in neuromyelitis optica/neuromyelitis optica spectrum disorders (NMO/NMOSD).Keywords
This publication has 18 references indexed in Scilit:
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- CSF interleukin-6 level predicts recovery from neuromyelitis optica relapseJournal of Neurology, Neurosurgery & Psychiatry, 2011
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis opticaProceedings of the National Academy of Sciences, 2011
- EFNS guidelines on diagnosis and management of neuromyelitis opticaEuropean Journal of Neurology, 2010
- Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivoAnnals of Neurology, 2009
- Treatment of Neuromyelitis Optica With Mycophenolate MofetilArchives of Neurology, 2009
- Intrathecal pathogenic anti–aquaporin‐4 antibodies in early neuromyelitis opticaAnnals of Neurology, 2009
- Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis opticaNeurology, 2007
- The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 1999
- ON THE OPHTHALMOSCOPIC SIGNS OF SPINAL DISEASE.The Lancet, 1870